

SUPPLEMENTAL MATERIAL

Table S1: Power estimates of hazard ratios for incident CVD based on rs4680 G(val) allele frequencies over range of GAF from 0.3-0.6.

GAF	HR	Power
0.30	0.70	0.98
	0.75	0.91
	0.80	0.74
0.40	0.70	0.99
	0.75	0.95
	0.80	0.80
0.50	0.70	0.99
	0.75	0.96
	0.80	0.83
0.60	0.70	0.99
	0.75	0.96
	0.80	0.82

Abbreviations: HR=Hazard Ratio; GAF= Gene allele frequency

Table S2: Demographics, baseline characteristics and aspirin use by *COMT* rs4818 genotype use in MESA.

	CC	GC	GG
Participants, n	2888 (47.7)	2515 (41.6)	649 (10.7)
Demographic data			
Age	62.1 (10.1)	62.3 (10.4)	63.0 (10.5)
Female	1501 (52.0)	1315 (52.3)	340 (52.4)
Race/ethnicity			
White	828 (28.7)	1129 (44.9)	379 (58.4)
Black	981 (34.0)	528 (12.9)	72 (11.1)
Hispanic	733 (25.4)	533 (21.0)	110 (17.0)
Asian	346 (12.0)	325 (21.2)	88 (13.6)
Medical History			
History of diabetes	395 (13.7)	312 (12.4)	54 (8.4)
Current smoker	373 (12.9)	338 (13.4)	66 (10.2)
Aspirin Use at Exam 1 (%)	579 (20.1)	512 (20.4)	126 (19.4)
Physical Exam			
Body mass index, kg/m ²	28.7 (5.7)	28.1 (5.4)	27.8 (5.1)
Systolic blood pressure, mmHg	127.5 (21.7)	126.0 (21.6)	124.8 (20.7)
Diastolic blood pressure, mmHg	72.3 (10.4)	71.5 (10.3)	71.2 (9.7)
Laboratory Measurements			
HDL cholesterol, mg/dL	50.6 (14.7)	50.8 (14.9)	51.0 (14.4)
Triglycerides, mg/dL	131.3 (87.7)	134.9 (96.9)	133.9 (79.2)
Total cholesterol, mg/dL	193.5 (35.8)	194.6 (36.6)	195.2 (34.3)

Table S3: Distribution of *COMT* rs4818 and rs4680 genotypes by race in MESA.

Race	rs4818					rs4680					LD r ²
	GG	GC	CC	MAF (G)	HWE	AA	AG	GG	MAF (A)	HWE	
Overall	677	2635	3004	0.32	<0.01	1106	2928	2316	0.40	<0.001	0.31
White	406	1206	869	0.41	>0.05	655	1236	593	0.51	>0.05	0.72
Black	74	547	1018	0.21	>0.05	178	685	806	0.31	>0.05	0.12
Hispanic	109	555	764	0.27	>0.05	211	704	514	0.39	>0.05	0.24
Asian	88	327	353	0.33	>0.05	62	303	403	0.28	>0.05	0.19

Abbreviations: MAF = minor allele frequency; HWE = Hardy-Weinberg Equilibrium; LD = Linkage disequilibrium

Table S4: Parameter estimates of COMT rs4818 and rs4680 (per G allele) association with baseline cardiometabolic risk factors.

Risk Factor		All			White			Black			Hispanic			Asian		
		Beta	SE	P	Beta	SE	P	Beta	SE	P	Beta	SE	P	Beta	SE	P
Fibrinogen, mg/dL	rs4818	-3.65	1.35	0.007	-0.81	2.11	0.70	-2.29	3.03	0.45	-4.94	3.02	0.10	-9.70	3.06	0.002
	rs4680	0.53	1.29	0.68	0.84	1.96	0.67	1.70	2.78	0.54	-1.43	2.89	0.62	0.54	3.31	0.87
CRP, mg/L	rs4818	-0.06	0.10	0.58	0.32	0.16	0.05	-0.19	0.33	0.58	-0.44	0.23	0.05	-0.31	0.20	0.12
	rs4680	0.17	0.11	0.11	0.33	0.15	0.03	0.09	0.27	0.74	0.003	0.22	0.99	-0.01	0.27	0.97
ICAM, ng/mL	rs4818	-1.05	2.22	0.64	-2.86	2.93	0.33	10.52	7.85	0.18	-3.22	5.84	0.58	1.09	4.95	0.82
	rs4680	-1.12	2.11	0.59	-1.20	2.77	0.66	3.83	6.92	0.58	-0.34	5.66	0.95	-3.97	4.91	0.42
IL-6, pg/mL	rs4818	-0.02	0.02	0.44	0.03	0.04	0.37	-0.01	0.06	0.91	-0.05	0.05	0.30	-0.09	0.05	0.08
	rs4680	0.02	0.04	0.50	0.02	0.03	0.47	0.03	0.05	0.59	0.10	0.04	0.02	-0.10	0.06	0.13
SBP, mmHg	rs4818	-0.23	0.39	0.56	0.13	0.56	0.81	-0.12	0.93	0.90	-0.49	0.83	0.55	-1.28	1.08	0.24
	rs4680	0.01	0.36	0.99	0.17	0.52	0.74	0.21	0.78	0.78	-0.45	0.76	0.55	-0.16	1.07	0.88
DBP, mmHg	rs4818	0.03	0.19	0.88	0.16	0.28	0.55	0.03	0.46	0.96	-0.25	0.38	0.52	0.06	0.52	0.91
	rs4680	0.03	0.18	0.85	0.09	0.26	0.74	-0.03	0.37	0.94	-0.30	0.36	0.41	0.71	0.56	0.21
Hemoglobin A1c, %	rs4818	-0.02	0.02	0.22	0.00	0.02	0.95	-0.07	0.05	0.15	-0.05	0.06	0.34	-0.07	0.04	0.12
	rs4680	-0.02	0.01	0.20	-0.01	0.02	0.41	-0.01	0.04	0.86	-0.02	0.06	0.69	-0.08	0.05	0.12
Fasting glucose, mg/dl	rs4818	-0.45	0.48	0.35	0.69	0.59	0.24	-3.36	1.34	0.01	-2.50	1.74	0.15	-2.36	1.39	0.09
	rs4680	-1.15	0.96	0.23	0.44	0.52	0.40	-1.69	1.21	0.16	-0.86	1.64	0.60	-3.86	1.65	0.02
Triglycerides, mg/dL	rs4818	0.17	1.66	0.92	-1.57	4.38	0.72	-0.12	4.71	0.98	0.60	2.56	0.81	0.51	3.00	0.86
	rs4680	-3.42	1.83	0.06	0.06	2.43	0.98	-4.14	3.33	0.21	-5.88	3.47	0.09	-8.52	4.90	0.08
HDL-C, mg/dL	rs4818	0.03	0.26	0.89	-0.05	0.41	0.90	-0.07	0.64	0.91	0.42	0.51	0.42	-0.22	0.62	0.72
	rs4680	0.33	0.24	0.17	-0.03	0.40	0.93	0.43	0.52	0.41	0.60	0.44	0.18	0.59	0.69	0.39
LDL-C, mg/dL	rs4818	0.08	0.63	0.90	0.75	0.92	0.42	-0.69	1.53	0.65	-0.79	1.37	0.56	0.10	1.55	0.95
	rs4680	-0.14	0.58	0.81	0.13	0.86	0.88	-1.11	1.24	0.37	-0.74	1.27	0.56	1.79	1.76	0.31

Table S5: *COMT* rs4818 and rs4680 gene dosage (per allele*) association with rates of CVD stratified by race and sex.

SNP	Females			Males			
	Race/Ethnicity	Events/N	HR 95% CI	P	Events/N	HR, 95% CI	P
rs4818							
Overall		226/3271	0.93 [0.75-1.14]	0.48	298/2977	0.80 [0.67-0.97]	0.02
White		97/1300	1.04 [0.77-1.41]	0.80	117/1179	0.85 [0.65-1.11]	0.24
Black		55/846	0.77 [0.45-1.32]	0.34	75/729	0.87 [0.58-1.32]	0.52
Hispanic		54/736	0.75 [0.47-1.18]	0.21	83/690	0.67 [0.46-0.98]	0.04
Asian		20/389	0.94 [0.50-1.79]	0.86	23/379	0.83 [0.42-1.64]	0.59
rs4680							
Overall		226/3271	0.95 [0.78-1.15]	0.59	298/2977	0.95 [0.79-1.14]	0.59
White		97/1300	1.14 [0.85-1.52]	0.38	117/1179	0.95 [0.73-1.22]	0.68
Black		55/846	0.88 [0.61-1.29]	0.52	75/729	1.04 [0.72-1.48]	0.84
Hispanic		54/736	0.75 [0.51-1.11]	0.15	83/690	1.04 [0.76-1.43]	0.79
Asian		20/389	0.89 [0.43-1.81]	0.74	23/379	0.55 [0.30-1.03]	0.06

Abbreviations: HR = Hazard ratio

* Allele key: rs4818 coded allele = G; rs4680 coded allele = G

Table S6: Hormone replacement therapy (HRT) use among women assessed at Exam 1 and rates of CVD by *COMT* rs4818 and rs4680 genotype stratified by HRT use and race.

Hormone replacement therapy (HRT) use ever								
SNP	Race/ethnicity	Total (%)	CC	GC	GG	HRT ever – no*	HRT ever – yes*	P _{interaction}
rs4818	Overall	1540 (51.1)	708 (49.6)	647 (51.2)	185 (57.6)	1.22 [0.74-2.02], 0.44	0.64 [0.45-0.89], 0.009	0.047
	White	772 (64.1)	269 (64.7)	367 (62.2)	136 (68.3)	2.20 [1.34-3.07], 0.002	0.59 [0.39-0.89], 0.01	0.02
	Black	384 (47.4)	241 (48.5)	127 (45.0)	16 (50.0)	0.94 [0.49-1.78], 0.84	0.96 [0.41-2.30], 0.94	0.97
	Hispanic	268 (40.6)	144 (39.9)	107 (42.3)	17 (37.0)	0.83 [0.51-1.34], 0.44	0.62 [0.17-1.31], 0.46	0.39
	Asian	116 (34.2)	54 (34.8)	46 (32.9)	16 (36.4)	1.28 [0.53-3.07], 0.58	0.59 [0.22-1.58], 0.30	0.84
			met/met	val/met	val/val			
rs4680	Overall	1701 (55.4)	296 (57.7)	723 (51.8)	521 (47.1)	1.14 [0.66-1.95], 0.64	0.75 [0.56-1.02], 0.07	0.26
	White	772 (64.1)	205 (66.8)	381 (63.0)	186 (62.5)	2.39 [1.42-4.01], 0.001	0.72 [0.49-1.04], 0.08	2E-04
	Black	419 (50.9)	45 (50.6)	158 (47.9)	181 (46.2)	0.93 [0.57-1.53], 0.78	0.96 [0.47-1.95], 0.91	0.43
	Hispanic	302 (45.1)	39 (41.5)	138 (40.8)	91 (39.9)	0.83 [0.54-1.28], 0.40	0.59 [0.22-1.61], 0.31	0.26
	Asian	137 (39.6)	7 (30.4)	46 (37.4)	63 (32.6)	0.81 [0.30-2.19], 0.68	0.88 [0.30-2.61], 0.82	0.24

Random effects meta-analysis of HRT ever and never use. I^2 for rs4818 HRT no = 65.1; HRT yes = 0. I^2 for rs4680 HRT no = 72.7; HRT yes = 0

Table S7: Aspirin user (%) > 3 days/week by *COMT* rs4818 genotype at the five MESA exams.

Exam	rs4818 genotype		
	CC	GC	GG
1	577 (20.0)	511 (20.3)	125 (19.3)
2	863 (31.6)	762 (31.4)	185 (29.2)
3	886 (33.9)	799 (34.6)	195 (32.3)
4	944 (37.2)	824 (36.4)	216 (36.0)
5	905 (45.2)	825 (44.4)	215 (44.4)

Supplementary Table S8: *COMT* rs4818 and rs4680 gene dosage (per allele*) association with rates of CVD stratified by time-varying aspirin and HRT ever use among white women.

SNP	Aspirin	No HRT	Ever HRT
		HR [95% CI], P	HR [95% CI], P
rs4818	<3 days/week	3.13 [1.53-6.39], 0.002	0.34 [0.16-0.69], 0.004
	≥3 days/week	1.99 [0.90-4.40], 0.09	0.80 [0.42-1.52], 0.49
	P_{interaction}	0.39	0.08
rs4680	<3 days/week	3.02 [1.38-6.58], 0.006	0.46 [0.25-0.85], 0.01
	≥3 days/week	2.25 [0.97-5.24], 0.06	1.27 [0.69-2.35], 0.45
	P_{interaction}	0.613	0.02

* Allele key: rs4818 coded allele = G; rs4680 coded allele = G